EichorEICHOR
Study identifier: NCT05345587 Synced from ClinicalTrials.gov · August 07, 2026
● Study status: Recruiting

Quality of Life and Economic Repercussions of Combining Proactive Medication Assessment and Electronic Monitoring of Toxicities in Subjects Undergoing Oral Cancer Therapy

Condition: Cancer  ·  Sponsor: Centre Hospitalier Universitaire de Nīmes

PhaseNA
Planned participants196
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.

About this study

Therapies used to treat cancer are administered orally (OT) in 75% of cases, lending themselves to outpatient care. This care pathway raises new issues: specific toxicities, drug interactions, and the relationship between the community (physicians and pharmacists) and the hospital. Drug interactions can increase toxicities or decrease the effectiveness of treatment and impact overall survival. Detection of drug interactions before treatment initiation is not always performed in routine practice. However, these oral treatments have a low therapeutic index and are associated with side effects that can alter quality of life (QoL). They are classically documented by the physician at the time of the consultation using the Common Terminology Criteria for Adverse Events (CTCAE), which makes it possible to adapt management. Nevertheless, numerous studies have shown a discrepancy between side effects reported by the patient versus those recorded by the physician, who tends to underestimate the intensity of the effects experienced by the patient. Studies have shown an improvement in the overall survival and QoL of patients followed by electronic patient reported outcomes (ePRO) compared to patients followed conventionally. Therefore, for this study, the study investigators aim to measure the impact of a care pathway associating a scheduled consultation with the hospital clinical pharmacist integrating a proactive medication assessment and the search for drug interactions and a follo…

This description comes directly from the study's public registry record.

Talk to the study team

Frédéric Fiteni  ·  04.34.03.46.69  ·  frederic.fiteni@chu-nimes.fr

Always discuss trial participation with your own doctor first.

Locations (6)

Centre Hospitalier Dubois BriveBrive-la-Gaillarde, FranceRecruiting
Chic Castres-MazametCastres, FranceRecruiting
Centre Hospitalier Emile ROUXLe Puy-en-Velay, FranceRecruiting
CHU de NîmesNîmes, FranceRecruiting
Institut cancerologie du GardNîmes, FranceRecruiting
Médipôle Lyon-VilleurbanneVilleurbanne, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →